Peng Foo Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Peng Foo Wong has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Reza Mofidi
Department of Vascular Surgery, James Cook University Hospital, Middlesbrough, UK
5 shared publications Gerard Stansby
Freeman Hospital Northern Vascular Centre Newcastle upon Tyne UK
3 shared publicationsSimon Milburn
Department of Interventional Radiology, James Cook University Hospital, Middlesbrough, UK
3 shared publicationsDavid J Leaper
Cardiff University; Department of Wound Healing; Heath Park Cardiff Wales UK CF14 4XN
2 shared publicationsS. Kumar
Professorial Unit of Surgery, University Hospital of North Tees, Stockton-on-Tees TS19 8PE, UK
2 shared publicationsSenthil Kumar
Professorial Unit of Surgery, University Hospital of North Tees, Stockton-on-Tees, UK
2 shared publications
Latest Publications
- 9 December 2024
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (4) , 590-598
Prediction of Two Year Survival Following Elective Repair of Abdominal Aortic Aneurysms at A Single Centre Using A Random Forest Classification Algorithm
- 9 December 2024
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 69 (4) , 590-598
Prediction of Two Year Survival Following Elective Repair of Abdominal Aortic Aneurysms at A Single Centre Using A Random Forest Classification Algorithm
- 23 January 2019
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 58, 222-231
Aneurysm Morphology Is a More Significant Predictor of Survival than Hardman's Index in Patients with Ruptured or Acutely Symptomatic Abdominal Aortic Aneurysms
- 23 January 2019
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 58, 222-231
Aneurysm Morphology Is a More Significant Predictor of Survival than Hardman's Index in Patients with Ruptured or Acutely Symptomatic Abdominal Aortic Aneurysms
- 1 December 2018
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 56 (6) , 784-792
Do Integrated Systems of Stroke Care Improve Symptom to Surgery Times in Patients with Symptomatic Carotid Stenosis? A Single Centre Decision Tree Analysis
- 1 December 2018
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 56 (6) , 784-792
Do Integrated Systems of Stroke Care Improve Symptom to Surgery Times in Patients with Symptomatic Carotid Stenosis? A Single Centre Decision Tree Analysis
- 20 April 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (4)
Endoluminal stents for iliac and infrainguinal arterial disease
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to assess the effects of different types of endoluminal stents (for example, bare metal, covered, drug‐eluting) against each other for restoration of patency in iliac, SFA, popliteal and infrapopliteal artery occlusions or stenoses. The secondary objectives are to assess the effectiveness of different types of stents in a) different participants (that is participants with claudication compared with participants with critical limb ischaemia) and b) different types of lesions based on the Trans‐Atlantic Inter‐Society Consensus II for each anatomical region (iliac, SFA, popliteal and infrapopliteal) (Dormandy 2000; Jaff 2015). In the absence of TASC II classifications, we will perform subgroup analyses with the lesions stratified into short (≤ 10 cm) or long (> 10 cm) stenosis or occlusion.
- 20 April 2017
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2017 (4)
Endoluminal stents for iliac and infrainguinal arterial disease
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: The primary objective is to assess the effects of different types of endoluminal stents (for example, bare metal, covered, drug‐eluting) against each other for restoration of patency in iliac, SFA, popliteal and infrapopliteal artery occlusions or stenoses. The secondary objectives are to assess the effectiveness of different types of stents in a) different participants (that is participants with claudication compared with participants with critical limb ischaemia) and b) different types of lesions based on the Trans‐Atlantic Inter‐Society Consensus II for each anatomical region (iliac, SFA, popliteal and infrapopliteal) (Dormandy 2000; Jaff 2015). In the absence of TASC II classifications, we will perform subgroup analyses with the lesions stratified into short (≤ 10 cm) or long (> 10 cm) stenosis or occlusion.
- 1 September 2016
- Published by Elsevier in Reviews in Vascular Medicine
- Vol. 6-7, 29-36
Assessment of quality of care in vascular surgery and the emergence of quality improvement programs
- 1 September 2016
- Published by Elsevier in Reviews in Vascular Medicine
- Vol. 6-7, 29-36
Assessment of quality of care in vascular surgery and the emergence of quality improvement programs
- 1 September 2016
- Published by Elsevier in Reviews in Vascular Medicine
- Vol. 6-7, 1-9
Value based healthcare and delivery of vascular surgery services in the United Kingdom
- 1 September 2016
- Published by Elsevier in Reviews in Vascular Medicine
- Vol. 6-7, 1-9
Value based healthcare and delivery of vascular surgery services in the United Kingdom
- Open Access
- 1 March 2014
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 27 (3) , e19-e20
Complete Endovascular Management of a Spontaneous Aorto-left Renal Vein Fistula Caused by Ruptured Abdominal Aortic Aneurysm Under Local Anaesthetic: A Case Report
- 1 March 2014
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 27 (3) , e19-e20
Open AccessComplete Endovascular Management of a Spontaneous Aorto-left Renal Vein Fistula Caused by Ruptured Abdominal Aortic Aneurysm Under Local Anaesthetic: A Case Report
- 16 July 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2015 (5) , CD003074
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
In the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear whether a once daily treatment regimen is as safe and effective as a twice daily treatment regimen. This is the second update of a review first published in 2003. To compare the efficacy and safety of once daily versus twice daily administration of LMWH. For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 2013) and CENTRAL (2013, Issue 4). Randomised clinical trials in which LMWH given once daily is compared with LMWH given twice daily for the initial treatment of VTE. Two review authors assessed trials for inclusion and extracted data independently. Five studies were included with a total of 1508 participants. The pooled data showed no statistically significant difference in recurrent VTE between the two treatment regimens (OR 0.82, 0.49 to 1.39; P = 0.47). A comparison of major haemorrhagic events (OR 0.77, 0.40 to 1.45; P = 0.41), improvement of thrombus size (OR 1.41, 0.66 to 3.01; P = 0.38) and mortality (OR 1.14, 0.62 to 2.08; P = 0.68) also showed no statistically significant differences between the two treatment regimens. None of the five included studies reported data on post-thrombotic syndrome. Once daily treatment with LMWH is as effective and safe as twice daily treatment with LMWH.
- 16 July 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2015 (5) , CD003074
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism
In the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear whether a once daily treatment regimen is as safe and effective as a twice daily treatment regimen. This is the second update of a review first published in 2003. To compare the efficacy and safety of once daily versus twice daily administration of LMWH. For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched May 2013) and CENTRAL (2013, Issue 4). Randomised clinical trials in which LMWH given once daily is compared with LMWH given twice daily for the initial treatment of VTE. Two review authors assessed trials for inclusion and extracted data independently. Five studies were included with a total of 1508 participants. The pooled data showed no statistically significant difference in recurrent VTE between the two treatment regimens (OR 0.82, 0.49 to 1.39; P = 0.47). A comparison of major haemorrhagic events (OR 0.77, 0.40 to 1.45; P = 0.41), improvement of thrombus size (OR 1.41, 0.66 to 3.01; P = 0.38) and mortality (OR 1.14, 0.62 to 2.08; P = 0.68) also showed no statistically significant differences between the two treatment regimens. None of the five included studies reported data on post-thrombotic syndrome. Once daily treatment with LMWH is as effective and safe as twice daily treatment with LMWH.
- 6 March 2013
- Published by American Medical Association (AMA) in JAMA
- Vol. 309 (9) , 926-927
Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication
Clinical Question Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality? Bottom Line In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.
- 6 March 2013
- Published by American Medical Association (AMA) in JAMA
- Vol. 309 (9) , 926-927
Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication
Clinical Question Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality? Bottom Line In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.
- 1 April 2012
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 27 (2_suppl) , 2-11
Epidemiology, risk factors and sequelae of venous thromboembolism
The aim of this review was to discuss the epidemiology, risk factors and sequelae of venous thromboembolism (VTE). VTE has an incidence of 1–2 per 1000 people annually. The risk of VTE increases with age and is highest in Caucasians and African Americans. Combined oral contraceptives (COC), especially the third-generation COCs, have been strongly implicated in VTE. Hospitalized patients, especially patients with underlying malignancy and undergoing surgery, have a host of risk factors for VTE. Thrombophilia can predispose an individual to VTE but indiscriminate testing for thrombophilia in patients presenting with VTE is not indicated. VTE can have serious chronic sequelae in the form of post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTPH). The risk of PTS and CTPH is increased with recurrent deep vein thrombosis and pulmonary embolism, respectively. Mortality from VTE can be as high as 21.6% at one year. Patients who had an episode of VTE have a high risk of subsequent VTE and this risk is highest in patients who had a first VTE event associated with malignancy. A good understanding of the epidemiology and risk factors of VTE will enable the treating medical practitioners to identify patients at risk and administer appropriate VTE prophylaxis to prevent the longterm consequences of VTE.
- 1 April 2012
- Published by SAGE Publications in Phlebology: The Journal of Venous Disease
- Vol. 27 (2_suppl) , 2-11
Epidemiology, risk factors and sequelae of venous thromboembolism
The aim of this review was to discuss the epidemiology, risk factors and sequelae of venous thromboembolism (VTE). VTE has an incidence of 1–2 per 1000 people annually. The risk of VTE increases with age and is highest in Caucasians and African Americans. Combined oral contraceptives (COC), especially the third-generation COCs, have been strongly implicated in VTE. Hospitalized patients, especially patients with underlying malignancy and undergoing surgery, have a host of risk factors for VTE. Thrombophilia can predispose an individual to VTE but indiscriminate testing for thrombophilia in patients presenting with VTE is not indicated. VTE can have serious chronic sequelae in the form of post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTPH). The risk of PTS and CTPH is increased with recurrent deep vein thrombosis and pulmonary embolism, respectively. Mortality from VTE can be as high as 21.6% at one year. Patients who had an episode of VTE have a high risk of subsequent VTE and this risk is highest in patients who had a first VTE event associated with malignancy. A good understanding of the epidemiology and risk factors of VTE will enable the treating medical practitioners to identify patients at risk and administer appropriate VTE prophylaxis to prevent the longterm consequences of VTE.